Researchers develop new drug for cystic fibrosis
The study demonstrated that the drug improved lung function, quality of life and showed reduction in disease flare ups in patients who have the ‘Celtic Gene,’ (G551D). The
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.